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Background: Kasabach-Merritt syndrome (KMS) is characterized by giant hemangiomas and severe
thrombocytopenia, which may result in life-threatening multi-organ hemorrhage. This study evaluated the clinical
characteristics, treatments, and outcomes in neonates with KMS, in order to find out the optimal therapy.
Methods: The clinical data of 17 patients treated for KMS in the Department of Neonates, Guangzhou Women and
Children’s Medical Center, Guangzhou Medical University, China from January 2007 to January 2012 were
retrospectively analyzed.
Results: The patients were 13 males and 4 females, aged 17 hours to 28 days at admission. Four patients had
visceral hemangiomas and 13 had cutaneous hemangiomas. All had thrombocytopenia and coagulation disorders.
Intravenous steroid therapy was initially effective in 6 patients (of which 3 relapsed) and ineffective in 11. The 11
patients with a poor response to steroids and the 3 who relapsed underwent arterial embolization therapy, which
was effective in 9 patients (of which 1 relapsed), ineffective in 4, and discontinued before completion in 1.
Subsequently, four patients in whom arterial embolization therapy was ineffective and one with relapse were
treated with vincristine. This was effective in four patients, and the other died of disseminated intravascular
coagulation. Steroid therapy was effective in 35.3% of patients, but the relapse rate was 50%. Arterial embolization
was effective in 64.3% of patients and vincristine was effective in 80%.
Conclusions: In patients with neonatal KMS, steroid therapy has a low rate of effectiveness and high rate of
relapse. Arterial embolization has a good rate of effectiveness. Combined steroid and embolization therapy should
be considered for first-line treatment of neonatal KMS. If this approach is ineffective, vincristine may be useful.
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Kasabach-Merritt syndrome (KMS), also known as giant
hemangioma with thrombocytopenia, was first reported
by Kasabach and Merritt in 1940. KMS accounts for about
1% of cases of hemangioma. KMS is characterized by giant
hemangiomas and severe thrombocytopenia, which may
result in life-threatening multi-organ hemorrhage. About
80% of patients present within 1 year after birth, and the
reported mortality rate ranges from 10% to 37% [1]. How-
ever, the optimal therapy for neonatal KMS is currently
unclear. From January 2007 to January 2012, 17 patients
with KMS were admitted to the Department of Neonates* Correspondence: zhouwei_pu002@126.com
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unless otherwise stated.at Guangzhou Women and Children’s Medical Center in
China.Methods
Subjects
From January 2007 to January 2012, 17 patients with
giant hemangioma who were eventually diagnosed with
KMS were admitted to the Department of Neonates at
Guangzhou Women and Children’s Medical Center,
China.Diagnostic criteria
The diagnostic criteria for KMS were as follows: (1)
hemangioma of the skin or internal organs; (2)
thrombocytopenia and consumptive coagulopathy; (3)
hemangioma confirmed by B-mode ultrasonography,td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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(CT), or magnetic resonance imaging (MRI); (4) other
causes for the abnormalities excluded, such as hypers-
plenism or idiopathic thrombocytopenic purpura.
The diagnostic criteria for disseminated intravascular
coagulation (DIC) followed overt DIC criteria by ISTH
(Table 1).
Consent
Written informed consents were obtained from the
patients for publication of this case report and any
accompanying image. Copies of the written consents are
available for review by the Editor of this journal.
Ethics
The research has been approved by GuangzhouWomen and
Children’s Medical Center’s appropriate ethics committee.
Clinical features
The appearances, characteristics, and complications of
hemangioma in the 17 neonates with KMS were summa-
rized and analyzed.
Therapeutic methods
The 17 neonates with KMS were treated with steroid
therapy, arterial embolization, and vincristine, depending
on their individual responses to treatment.
Results
Patient characteristics
The 17 patients with KMS included 13 males and 4
females. Their age at admission ranged from 17 hours to
28 days. One patient was born prematurely (34+5 weeks
gestation), and the remainder were born at term. The
birth weight ranged from 2300 g to 4000 g.
Clinical manifestations
Of the 17 patients, 4 had visceral hemangiomas, including
1 patient with multiple cutaneous hemangiomas (moreTable 1 The diagnostic criteria of DIC by ISTH
Overt DIC by ISTH
Platelet Count 50,000 ~ 100,000/ul 1 point
<50,000/ul 2 points
PT Prolongation of PT
3 ~ 6 sec 1 point
> 6 sec 2 points
Fibrinogen < 100 mg/dl 1 point
D-dimer 0.5 – 1 1 point
1 – 2 2 points
> = 2(μg/ml) 3 points
Total Overt DIC > =5 pointsthan 20 hemangiomas of different sizes) and multiple
hepatic hemangiomas, 1 patient with a right subman-
dibular racemose hemangioma, 1 patient with a giant
hepatic hemangioma, and 1 patient with an intracranial
hemangioma. The remaining 13 patients had cutaneous
hemangiomas only. The locations of cutaneous hem-
angiomas varied widely. Cutaneous hemangiomas ap-
peared as violet or dark red lesions with obvious swelling,
increased tension, slightly increased skin temperature, un-
clear boundaries, and a firm or hard texture (Figure 1).
Seven patients had large numbers of bleeding points and
ecchymosis. In one case, right submaxillary ecchymosis
and thrombocytopenia were detected during the neonatal
period, leading to a diagnosis of thrombocytopenic pur-
pura at the local hospital. The patient was transferred to
Guangzhou Women and Children’s Medical Center for
treatment of a pericardial effusion. CT showed a racem-
ose hemangioma of the pericardium, and B-mode ultra-
sonography showed a right submaxillary subcutaneous
hemangioma. In another case, the patient was jaundiced
at admission, and the right eye protruded further than
the left eye. The patient had a black rash on his right
upper eyelid, and a large amount of ascites. Brain MRI
showed a hemangioma arising from a vascular malforma-
tion in the right cavernous sinus and right eye socket.
Laboratory examination findings
Laboratory examination findings showed a mean platelet
count of 31.1 ± 21.7 × 109/L (range 2–119 × 109/L),
hemoglobin concentration of 94.1 ± 21.1 g/L (range 66–
128 g/L), prothrombin time of 28 ± 5.6 s (range 13–38 s)
with a prolonged prothrombin time in 15 patients, throm-
bin time of 18 ± 3.6 s (range 15–28 s) with a prolonged
thrombin time in 5 patients, activated partial thrombo-
plastin time of 51 ± 5.8 s (range 40–72 s) with a prolonged
activated partial thromboplastin time in 8 patients, and
fibrinogen level of 0.8 ± 0.37 mg/dL (range 0.34-1.8 mg/dL)
with a low fibrinogen level in 15 patients. Two patients met
the diagnostic criteria for DIC.
Treatment
The 17 patients received sequential combined therapy.
The initial therapy was supportive. Six patients with a
platelet count of <20 × 109/L received apheresis platelet
infusions. Eight patients with a fibrinogen level of <1.0
mg/dL received cryoprecipitate infusions. Intravenous dexa-
methasone 1 mg/kg/day was administered simultaneously
as first-line drug treatment. The platelet count started to
increase at 3–8 days after the start of treatment in seven pa-
tients, reaching a normal value at 16–28 days. Coagulation
function improved, and no bursting or bleeding of he-
mangiomas was observed. After the platelet count returned
to normal, we evaluated the effectiveness of the therapeutic




Figure 1 Images of four patients. (A) The patient with multiple cutaneous hemangiomas (more than 20 hemangiomas of different sizes) and
multiple hepatic hemangiomas. (B) The patient with cutaneous hemangiomas on back and axilla. (C) The patient with cutaneous hemangiomas
on left leg. (D) The patient with cutaneous hemangiomas on right knee.
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tients were discharged on medication. The six patients who
responded well to steroid therapy were regularly followed
up at the hospital. In three patients, the platelet counts
remained normal for the following year. The hemangiomas
did not enlarge or bleed, and regressed within 1–2 years. In
the other three patients, the platelet counts subsequently
decreased (at 30 days, 3 months, and 5 months after treat-
ment), and they were re-admitted to hospital and under-
went arterial embolization. No relapses were observed over
the following year.
The other 11 patients received supportive treatment and
steroid therapy for 10 days, but their platelet counts
remained low, and the hemangiomas bled in some cases.
One patient discontinued therapy because of the severity
of disease and financial difficulty. The remaining 10 pa-
tients underwent arterial embolization. The femoral arterywas cannulated under general anesthesia using the
Seldinger technique. A 3-F or 4-F cannula was intro-
duced and the patient was heparinized. A 3-F or 4-F
Cobra catheter was introduced for arteriography, and
was advanced to the feeding artery of the hemangioma.
Arterial embolization was performed with a mixture of
bleomycin A5 (8–12 mg/m2), iodinated oil (2 mL), and
dexamethasone (2 mg). After removal of the catheter,
the bleeding was controlled by direct pressure for
15 min, and a pressure dressing was applied (Figure 2).
Six patients were given dexamethasone after arterial
embolization. The platelet counts increased at 2–5 days
after embolization, and reached normal levels at 10–16
days. The coagulation function was improved, and no
bursting or bleeding of hemangiomas was observed. Pa-
tients were followed up regularly after embolization.
Only one patient developed recurrence at 5 months
A B
Figure 2 Images of arterial embolization. (A) Right submaxillary hemangioma. (B) Right leg and ankle hemangioma.
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and vincristine chemotherapy (1 mg/m2 weekly). In the
remaining four patients, the platelet count decreased at
1 week after surgery. These patients were treated with vin-
cristine chemotherapy 1 mg/m2 weekly, resulting in im-
provement. Three of these patients did not relapse during
a year of follow-up, and the other patient died of severe
disseminated intravascular coagulation. In one patient
with intracranial hemangioma, the hemangioma regressed
during 2 years of follow-up (Figure 3). One patient devel-
oped a fever during treatment, and one developed
gastrointestinal adverse effects. No cases of bone mar-
row depression or neurotoxicity were observed.
Discussion
The main diagnostic features of KMS are giant hemangioma
and decreased platelet count. Giant cutaneous hemangiomasA
Figure 3 MRI of the intracranial hemangioma in one case with a huge
(A) Exophthalmos of the right eye and a huge intracranial hemangioma. (B
intracranial hemangioma.are easy to diagnose on physical examination. Visceral
hemangiomas are easily missed, and patients may
present with large ecchymoses. According to the cases
in this research, it illustrates that KMS should be con-
sidered in children with unexplained thrombocytopenia
and coagulation disorders. Routine blood testing showed
varying degrees of low hemoglobin concentration, low
plasma fibrinogen level, and prolonged prothrombin time.
B-mode ultrasonography, CT, and MRI showed the size,
appearance, and layers of hemangiomas, as well as their
relationships with peripheral vessels, and distinguished
hemangiomas from vascular malformations.
KMS is associated with Kaposi haemangioendothe-
lioma(KHE) in over 90% of cases according to the re-
search findings recently, and uncommonly with infantile
and congenital haemangioma. The MRI findings of KHE
have some characters. It presents as an enhancing, ill-B
intracranial hemangioma before and after treatment.
) Reduction of exophthalmos of the right eye, and regression of the
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tense on T1 weighted images and hyperintense on T2
weighted images compared with muscle. Prominent vas-
cular channels, presenting as flow voids in the tumour
or as linear enhancing channels adjacent to the tumour,
are usually noted [2]. However, these findings are not
specific for KHE. KHE can’t be confirmed by MRI only.
The identification of hemangioma type rely mainly on
pathologic examination, but KMS is associated with co-
agulation dysfunction, which is a contraindication of
pathological biopsy. So our patients accepted B-mode
ultrasonography, color Doppler flow imaging, or com-
puted tomography (CT) because of the cheaper costs.
Only one patient accepted MRI.
There are currently no consensus guidelines for the
treatment of KMS. Some studies have reported good
therapeutic effects with comprehensive sequential therapy,
including steroid therapy, interferon, arterial embolization,
vincristine, radiotherapy, and surgery [3-5]. There are no
specific guidelines for diagnosis and treatment during the
neonatal period.
In infants, glucocorticoid therapy is considered to be a
good choice for initial drug treatment, because it can in-
hibit fibrinolysis and thrombosis, stimulate hematopoiesis
in the bone marrow to increase release of platelets into
the bloodstream, decrease the level of anti-platelet anti-
bodies, and increase platelet count. However, it is only
effective in 30% to 50% of patients with KMS [6,7].
Glucocorticoid therapy may be administered orally,
intravenously, or locally; and commonly starts to show
effectiveness at 1–2 weeks after the onset of treatment
[8]. Our patients were treated with intravenous dexa-
methasone 1 mg/kg/day, and the platelet count started
to increase after 3–8 days. In this study, steroid therapy
was effective in 35.3% of patients, but the relapse rate
was high (50%), resulting in an eventual effectiveness
rate of only 17.6%. A more effective therapeutic
approach is therefore necessary.
In patients who responded poorly to steroid therapy,
arterial embolization was performed with bleomycin A5
(8–12 mg/m2), iodinated oil (2 mL), and dexamethasone
(2 mg). Arterial embolization has been used to treat vas-
cular tumors for many years [9,10], and is useful for
controlling symptoms and promoting regression of hem-
angiomas. However, neonates have tiny vessels, and do
not tolerate such intervention well. There have been a
few previous reports of treatment by arterial embolization
in neonates with KMS in China, especially in patients with
coagulation disorders. The dose of contrast agent needed,
risk associated with general anesthesia, and difficulty in
catheter placement limit the usefulness of this treatment
in neonates. In the present study, arterial embolization
was effective in 64.3% of patients. A previous study of ar-
terial embolization using bleomycin A5 found that partialembolization significantly improved coagulation function
and decreased hemangioma blood flow, and relieved
symptoms [11]. Another study found that local injection
of urea destroyed the vascular endothelial cell matrix, sup-
pressed endothelial cell growth, promoted endothelial cell
atrophy, caused fibrosis of local tissue, hardened the
tumor tissue, and caused thrombosis in the vascular
lumen of the tumor body [12]. Local injection of urea has
been used to successfully treat hemangiomas and vascular
malformations, and may be useful for the treatment of
neonatal KMS [12]. Arterial embolization in neonates is
difficult and carries some risks, but can improve the pa-
tient’s condition if intravenous drug therapy has not con-
trolled the hemangioma.
Intravenous vincristine has been used for the treat-
ment of KMS, and can be used as a first-line drug in the
treatment of Kaposiform hemangioendothelioma com-
bined with KMS [13,14]. An American multicenter study
found that vincristine therapy was useful in patients who
were resistant to steroid and interferon therapy [13,15].
Vincristine, actinomycin, and cyclophosphamide can in-
duce tumor regression and normalization of coagulation
parameters [16]. Although vincristine is neurotoxic, it
can help to alleviate symptoms in patients with KMS. In
this study, vincristine was administered to five patients
who responded poorly to steroid therapy and arterial
embolization, and was effective in 80% of these patients.
No adverse effects related to chemotherapy were ob-
served. These results indicate that vincristine can be
used to treat neonatal KMS. However, this study only
had a small number of subjects, and a larger sample is
needed to confirm the effectiveness of vincristine ther-
apy. Haisley-Royster et al. [13] reported that platelet
counts in patients with KMS increased to normal values
after 5 weeks of vincristine therapy. Vincristine therapy
cannot avoid hemangioma relapse, but has been re-
ported to result in prolonged reduction in hemangioma
growth [11], which is consistent with the findings of this
study.
It is worth noting that platelet transfusion is suitable
for increasing the platelet count urgently or preopera-
tively, but it cannot be used routinely, because the
hemangioma will consume the platelets [5,17,18]. More-
over, platelet transfusion will promote an increase in
hemangioma size by inducing blood coagulation [5,17,18].
Excessive platelet transfusion has been reported to aggra-
vate KMS [5,17,18]. In this study, patients received apher-
esis platelet transfusions if their platelet count was <20 ×
109/L, which allowed us to perform arterial embolization.
Transfusion therefore did not aggravate their condition.
Systemic interferon therapy has been used in patients
who were resistant to steroid therapy, with good results
[4,18]. However, the effectiveness of interferon therapy is
variable. Interferon therapy can be considered as a second-
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patients, but it only has weak inhibitory effects on endo-
thelial cell and vascular growth, and continuous treat-
ment is needed [19]. Continuous interferon therapy may
result in increased transaminase levels, decreased plate-
let count, and decreased leukocyte count [20]. A meta-
analysis by Michaud et al. [8] found that interferon
therapy could cause spastic diplegia and dyskinesia in
infants. They recommended that interferon therapy
should not be used in patients aged less than 1 year,
except when other treatment methods are ineffective
and the patient’s condition is life-threatening [8].
Leong et al. [21] reported two neonates with KMS
who received radiotherapy after full-dose steroid therapy
and α-interferon therapy were ineffective, resulting in a
rapid increase in platelet count. The hemangioma gra-
dually regressed over 3 years in one patient, and fully
regressed within 2 months in the other patient. No
adverse effects associated with radiotherapy were de-
tected during the follow-up periods of 8 and 5 years,
respectively, suggesting that radiotherapy may be a safe
and effective treatment for KMS. However, another
study reported that radiotherapy for hemangioma may
increase the frequency of secondary tumors [22]. The
safety and effectiveness of radiotherapy for the treatment
of KMS should be evaluated in further clinical studies
with follow-up over a few decades.
Conclusions
Neonatal KMS has a high relapse rate after steroid ther-
apy. Arterial embolization has a good rate of effectiveness.
Combined steroid therapy and arterial embolization can
be used as first-line treatment for neonatal KMS. If this
combination is ineffective, vincristine therapy may be
useful.
Abbreviations
KMS: Kasabach-Merritt syndrome; CT: Computed tomography; MRI:
Magnetic resonance imaging; DIC: Disseminated intravascular coagulation;
ISTH: International Society on Thrombosis and Haemostasis; KHE: Kaposi
haemangioendothelioma.
Competing interests
No benefits in any form have been received or will be received from any
commercial party related directly or indirectly to the subject of this article.
Author’s contributions
PW proposed the study and wrote the first draft. WZ guided the design of
the study and helped to draft the manuscript. LT participated in its design
and coordination and helped to revise the manuscript. NZ conceived of the
study, and helped the acquisition and interpretation of data. XWC helped to
draft the manuscript. All authors read and approved the final manuscript.
Author’s information
Ping Wang is the first author of this paper.
Acknowledgement
We thank Zhang Jing, Chen Kunshan, Zhou Shaoyi who provided acquisition
of data service in Interventional Radiology Department of Guangzhou
Women and Children’s Medical Center.Received: 8 November 2013 Accepted: 29 May 2014
Published: 11 June 2014
References
1. Kwok-Williams M, Perez Z, Squire R, Glaser A, Bew S, Taylor R: Radiotherapy
for life-threatening mediastinal haemangioma with kasabach-merritt
syndrome. Pediatr Blood Cancer 2007, 49:739–744.
2. Chen YJ, Wang CK, Tien YC, Hsieh TJ: MRI of multifocal kaposiform
haemangioendothelioma without kasabach-merritt phenomenon.
Br J Radiol 2009, 82:e51–e54.
3. Lei H, Sui B, Liu D: Comprehensive sequential therapy of kasabach-
merritt syndrome. Nat Med J China 2011, 91:2538–2541.
4. Yoon HS, Lee JH, Moon HN, Seo JJ, Im HJ, Goo HW: Successful
treatment of retroperitoneal infantile hemangioendothelioma with
kasabach-merritt syndrome using steroid, α-interferon, and vincristine.
J Pediatr Hematol Oncol 2009, 31:952–954.
5. Hauer J, Graubner U, Konstantopoulos N, Schmidt S, Pfluger T, Schmid I:
Effective treatment of kaposiform hemangioendotheliomas associated
with kasabach-merritt phenomenon using four-drug regimen.
Pediatr Blood Cancer 2007, 49:852–854.
6. Hesselmann S, Micke O, Marquardt T, Baas S, Bramswig JH, Harms E, Willich
N: Case report: kasabach-merritt syndrome: a review of the therapeutic
option and a case report of successful treatment with radiotherapy and
interferon alpha. Br J Radiol 2002, 75:180–184.
7. Taegyun K, Roh MR, Cho S, Chung KY: Kasabach-merritt syndrome arising
from tufted angioma successfully treated with systemic corticosteroid.
Ann Dermatol 2010, 22:426–430.
8. Michaud AP, Bauman NM, Burke DK, Manaligod JM, Smith RJ: Spastic
diplegia and other motor disturbances in Infants receiving
interferon-alpha. Laryngoscope 2004, 114:1231–1236.
9. O’Regan GM, Irvine AD, Yao N, O’Marcaigh A, Sheridan-Pereira M, Phelan E,
McDermott MB, Twomey A, Russell J, Watson R: Mediastinal and neck
kaposiform hemangioendothelioma:report of three cases.
Pediatr Dermatol 2009, 26:331–337.
10. Argenta LC, Bishop E, Cho KJ, Andrews AF, Coran AG: Complete resolution
of life-threatening hemangioma by embolization and cortico-steroids.
Plast Reconstr Surg 1982, 70:739–744.
11. Garcia-Monaco R, Giachetti A, Peralta O, Napoli N, Lobos P, Gioseffi L,
Mariani G: Kaposiform hemangioendothelioma with kasabach-merritt
phenomenon: successful treatment with embolization and vincristine in
two newborns. J Vasc Interv Radiol 2012, 23:417–422.
12. Dong C, Ma Y: Urea interventional therapy for severe maxillofacial
cavernous hemangioma. Chinese J Plastic Surg 2004, 20:316–317.
13. Haisley-Royster C, Enjolras O, Frieden IJ, Garzon M, Lee M, Oranje A,
de Laat PC, Madern GC, Gonzalez F, Frangoul H, Le Moine P, Prose
NS, Adams DM: Kasabach-merritt phenomenon: a retrospective
study of treatment with vincristine. J Pediatr Hematol Oncol 2002,
24:459–462.
14. López V, Martí N, Pereda C, Martín JM, Ramón D, Mayordomo E, Jordá E:
Successful management of kaposiform hemangioendothelioma with
kasabach-merritt phenomenon using vincristine and ticlopidine.
Pediatr Dermatol 2009, 26:365–366.
15. Abass K, Saad H, Kherala M, Abd-Elsayed AA: Successful treatment of
kasabach—merritt syndrome with vincristine and surgery: a case report
and review of literature. Cases J 2008, 1:9.
16. Hu B, Lachman R, Phillips J, Peng SK, Sieger L: Kasabaeh—merritt
syndrome associated kaposiform hemangioendothelioma successfully
treated with cyclophosphamide, vincristine, and aetinomycin D.
J Pediatr Hematol Oncol 1998, 20:567–569.
17. Phillips WG, Marsden JR: Kasabaeh-merritt syndrome exacerbated by
platelet transfusion. J R Soc Med 1993, 86:231–232.
18. Peker E, Kirimi E, Tuncer O, Ceylan A, Oner AF: Brachial plexus paralysis
due to giant cavernous hemangioma with kasabach-merritt syndrome:
successful management with interferon alpha. Platelets 2009, 20:603–605.
19. Sarkar M, Mulliken JB, Kozakewich HP, Robertson RL, Burrows PE:
Thrombocytopenic coagulopathy (kasabach- merritt phenomenon)is
associated with and not with kaposiform hemangioendothelioma
common infantile hemangioma. Plast Reconstr Surg 1997, 100:1377–1386.
20. Dubois J, Hershon L, Carmant L, Bélanger S, Leclerc JM, David M: Toxicity
profile of interferon alpha-2b in children: a prospective evaluation.
J Pediatr 1999, 135:782–785.
Wang et al. BMC Pediatrics 2014, 14:146 Page 7 of 7
http://www.biomedcentral.com/1471-2431/14/14621. Leong E, Bydder S: Use of radiotherapy to treat life-threatening
kasabach-merritt syndrome. J Med Imaging Radiation Oncol 2009,
53:87–91.
22. Lindberg S, Karlsson P, Arvidsson B, Holmberg E, Lunberg LM, Wallgren A:
Cancer incidence after radiotheraphy for skin hemangiomas during
infancy. Acta Oncol 1995, 34:735–740.
doi:10.1186/1471-2431-14-146
Cite this article as: Wang et al.: Clinical analysis of kasabach-merritt
syndrome in 17 neonates. BMC Pediatrics 2014 14:146.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
